Reducing inappropriate polypharmacy: the process of deprescribing by Scott, Ian A. et al.
Copyright 2015 American Medical Association. All rights reserved.
Reducing Inappropriate Polypharmacy
The Process of Deprescribing
Ian A. Scott, MBBS, FRACP, MHA, MEd; Sarah N. Hilmer, MBBS, FRACP, PhD; Emily Reeve, BPharm (Hons), PhD;
Kathleen Potter, PhD, FRACGP; David Le Couteur, PhD, FRACP;
Deborah Rigby, BPharm, GradDipClinPharm, FASCP, FACP, FAICD; Danijela Gnjidic, PhD;
Christopher B. Del Mar, MB, BChir, MD, FRACGP; Elizabeth E. Roughead, PhD; Amy Page, MClinPharm;
Jesse Jansen, MPsych, PhD; Jennifer H. Martin, MB, ChB, FRACP, PhD
I n developed countries, approximately 30% of patients aged65 years or older are prescribed 5 or more drugs.1 Whereasmany may benefit from such polypharmacy2 (defined here as
>5 regular prescribed drugs), it comes with increased risk of
adverse events in older people3 due to physiological changes of
aging that alter pharmacokinetic and pharmacodynamic
responses to drugs.4 Approximately 1 in 5 drugs commonly used in
older people may be inappropriate,5 increasing to one-third
among those living in aged care facilities.6 Among nursing home
residents with advanced dementia, more than half receive at least
1 drug with questionable benefit.7 Approximately 50% of hospital-
ized or ambulatory care patients or nursing home residents
receive 1 or more unnecessary drugs.8 Observational studies have
documented adverse drug events in at least 15% of older patients,
contributing to ill health,9 disability,10 hospitalization,11 and, in
some cases, death.12 This high level of iatrogenic harmmandates a
response from prescribing clinicians. The number of drugs that a
patient is taking is the single most important predictor of harm.13
In this article, we define the process of deprescribing potentially
inappropriate drugs, the evidence supporting the process, and
barriers and enablers to its adoption in routine clinical practice.
Whereas the focus here is on deprescribing prescription drugs in
older people, the same principles can be applied to any patient,
regardless of age, who is prescribed multiple long-term drugs, and
to all drugs, be they prescription or nonprescription drugs (alter-
native or complementary or over the counter).
Defining Deprescribing
Wedefinedeprescribingas thesystematicprocessof identifyingand
discontinuingdrugs in instances inwhichexistingorpotential harms
outweigh existing or potential benefits within the context of an in-
dividual patient’s caregoals, current level of functioning, life expec-
tancy,values, andpreferences.Deprescribing ispartof thegoodpre-
scribing continuum, which spans therapy initiation, dose titration,
changing or adding drugs, and switching or ceasing drug therapies.
Deprescribing is not about denying effective treatment to eligible
patients. It is a positive, patient-centered intervention, with inher-
ent uncertainties, and requires shared decision making, informed
patientconsent,andclosemonitoringofeffects—thesamegoodpre-
scribing principles that apply when drug therapy is initiated. It in-
volves diagnosing a problem (use of an inappropriate drug), mak-
inga therapeuticdecision (withdrawing itwith close follow-up), and
altering the natural history (reducing incidence of drug-related ad-
verseevents suchas falls, relievingadverseeffects, improving func-
Inappropriate polypharmacy, especially in older people, imposes a substantial burden of
adverse drug events, ill health, disability, hospitalization, and even death. The single most
important predictor of inappropriate prescribing and risk of adverse drug events in older
patients is the number of prescribed drugs. Deprescribing is the process of tapering or
stopping drugs, aimed at minimizing polypharmacy and improving patient outcomes.
Evidence of efficacy for deprescribing is emerging from randomized trials and observational
studies. A deprescribing protocol is proposed comprising 5 steps: (1) ascertain all drugs the
patient is currently taking and the reasons for each one; (2) consider overall risk of
drug-induced harm in individual patients in determining the required intensity of
deprescribing intervention; (3) assess each drug in regard to its current or future benefit
potential compared with current or future harm or burden potential; (4) prioritize drugs for
discontinuation that have the lowest benefit-harm ratio and lowest likelihood of adverse
withdrawal reactions or disease rebound syndromes; and (5) implement a discontinuation
regimen andmonitor patients closely for improvement in outcomes or onset of adverse
effects. Whereas patient and prescriber barriers to deprescribing exist, resources and
strategies are available that facilitate deliberate yet judicious deprescribing and deserve
wider application.
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tion,preventingprematuredeath).Deprescribingconsidersnotonly
the risk associatedwith individual drugsbut also thecumulative risk
from multiple drugs due to pharmacokinetic and pharmacody-
namic interactions.
Evidence of Efficacy of Deprescribing
Considerable observational evidence of the adverse effects of
polypharmacy in older patients indirectly supports the need for
deprescribing in this population.14,15 We obtained an overview of
more direct evidence of the efficacy and safety of deprescribing
by retrieving articles from Medline, the Cumulative Index to Nurs-
ing and Allied Health Literature, and the Cochrane Library using
the search terms “deprescribing,” “polypharmacy,” and “inappro-
priate medications.” Sentinel articles known us or found by scruti-
nizing reference lists of retrieved articles were also included. Pref-
erence was given to systematic reviews of randomized trials and
high-quality observational studies. Studies were grouped accord-
ing to whether they investigated effects of withdrawing specific
drugs or effects of multifaceted interventions aimed at reducing
inappropriate polypharmacy across multiple drug classes and clini-
cal settings.
DrugWithdrawal Trials
A systematic review of 31 withdrawal trials (15 randomized, 16
observational) of specific classes of drugs in people 65 years and
older demonstrated that, with appropriate patient selection and
education coupled with careful withdrawal and close monitoring,
use of antihypertensive agents, psychotropic drugs, and benzodi-
azepines could be discontinued without harm in between 20%
and 100% of patients.16 Withdrawal of agents in the latter 2
classes of drugs was associated with reduction in falls and
improvement in cognitive and psychomotor function, a finding
replicated in a more recent review.17 Another review of 9 random-
ized trials demonstrated the safety of withdrawing antipsychotic
agents that had been used continuously for behavioral and psy-
chological symptoms in more than 80% of participants with
dementia.18 The Australian National Blood Pressure study,
although not designed as a deprescribing trial, found that 37%
of participants remained normotensive 1 year after drug
withdrawal.19 In another observational study, cessation of inap-
propriate antihypertensive agents was associated with fewer car-
diovascular events and deaths over a 5-year follow-up period.20 In
another randomized trial, patient education provided through
community pharmacists led to a 77% reduction in benzodiazepine
use among long-term users at 6 months with no withdrawal sei-
zures or other ill effects.21 In an observational study of older out-
patients, 60% had 1 or more drugs successfully discontinued over
a 6-month period.22
Studies of Interventions for Reducing
Inappropriate Polypharmacy
Multifaceted interventions for reducing use of inappropriate drugs
comprise pharmacist or physician drug review, education pro-
grams, audit and feedback, geriatric assessment, and multidisci-
plinary team approaches. In a 2013 systematic review of 36 stud-
ies (including 20 controlled trials) involving 13 906 frail older
patients in various settings, 22 of 26 studies containing quantita-
tive data reported statistically significant reductions in the propor-
tions of drugs deemed unnecessary (defined using various crite-
ria), ranging from 3 to 20 percentage points.8 A 2013 Cochrane
analysis of 5 randomized trials of inpatient medication reviews led
by physicians, pharmacists, or other health professionals involving
1186 participants demonstrated a 36% reduction in emergency
department visits from 30 days to 1 year following discharge but
no effect on readmissions or mortality.23 A more recent review of
20 trials of pharmacist-led reviews in both inpatient and outpa-
tient settings involving 9858 participants showed no effects
except for reduction in unplanned hospitalizations in patients with
heart failure.24 A 2012 review of 10 controlled and 20 randomized
studies involving 247 674 older patients revealed statistically sig-
nificant reductions in the number of drugs in most of the con-
trolled studies, although mixed results in the randomized
studies.25 A 2012 Cochrane review of 10 studies of different
designs concluded that interventions were beneficial in reducing
inappropriate prescribing and drug-related problems.26 Another
2011 review of 20 randomized trials specific to nursing homes and
involving 14 416 residents concluded that educational interven-
tions and pharmacist drug review may reduce inappropriate drug
use under certain circumstances.27 A later 2013 Cochrane review
restricted to 8 randomized trials of various interventions involving
7653 nursing home residents suggested that drug-related prob-
lems were more frequently identified and resolved, together with
improvement in drug appropriateness.28 In general, studies were
highly heterogeneous in their interventions and measures of drug
use, analyses of appropriateness did not always separate under-
use of effective drugs from overuse of unnecessary drugs, meth-
odological quality was low to moderate, few reported impact on
patient outcomes, and follow-up periods were short. However,
the evidence overall suggests that deprescribing is feasible, safe,
and, in many instances, beneficial.
Among the small number of studies reporting patient out-
comescitedwithinthesereviews, themostnotableeffectswereseen
whenphysiciandrug reviewwascombinedwithapalliativecareper-
spective involvingdiscussionswith families andprimarycare teams.
In a controlled trial involving 190patients in agedcare facilities, this
approach resulted in63%ofpatientshavingameanof2.8drugsper
patient discontinued andwas associatedwith a halving in both an-
nualmortality and referrals toacutecarehospitals.29 Inanotherpro-
spective uncontrolled study, the same approach applied to a co-
hort of 70community-dwellingolder patients resulted in ameanof
4.4 drugs prescribed to 64 patients being recommended for dis-
continuation, of which 81% were successfully discontinued, with
88%ofpatients reportingglobal improvements inhealth.30 In2 ran-
domizedtrials conducted inagedcare facilitiesandcenteredonedu-
cational interventions, 1 aimed at prescribers,31 the other at nurs-
ing staff,32 the number of potentially harmful drugs and days in the
hospital was significantly reduced,31,32 combined with slower de-
clines in health-related quality of life.31
The Process of Deprescribing
In lightofevidencesupportingprescriber-mediateddrug review,we
propose a simple 5-step protocol to deprescribing outlined in the
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Table. An algorithm that guides the order and mode in which po-
tentially inappropriate drug use can be ceased is depicted in the
Figure. This protocol was iteratively developed by us on the basis
of research conducted by various members within our group.33,34
An earlier version of the protocol was shown to have face validity
amonga cohort of prescribers andpharmacists.35 Certain stepsde-
serve special mention.
DecidingWhich Drug Therapies Can Be Discontinued
What Are Current Indications for Each Drug?
Prescribers andpharmacistsmust collaborate in collecting asmuch
information as possible in answering the following questions: why
andwhenwas a therapy initiated;was the diagnosis substantiated;
was thedrugprescribed to counter adverse effects of another drug
(the prescribing cascade); is the drug continuing to confer evident
patientbenefit; are there alternative, equally effectivenonpharma-
cological therapies available? Somedrugs, beingwell tolerated, are
continued for years on the assumption that they are serving a use-
ful purpose.Drug regimens should comewith anexpiryor “best be-
fore” date prompting reappraisal, with earlier reviews conditional
on substantial change in a patient’s clinical status.
Examples of unnecessary continuation of drugs include pa-
tients receiving long-acting nitrates for a past episodeof chest pain
labeled as angina but in whom no objective evidence of coronary
artery disease exists, gastroprotective proton-pump inhibitors fol-
lowingcessationofnonsteroidalanti-inflammatorydrugtherapy,an-
tidepressants for a previous but resolved episode of reactive de-
pression, antihypertensives in patients now normotensive in
response to lifestylemodifications, and risperidone for distant epi-
sodes of excessive agitation complicating dementia.
Is the Patient Actually Taking the Drug?
Older patients avoid usingdrugs that they sense couldmake, or are
making, themfeel unwell, especiallyprophylacticdrugsaimedat re-
ducing risk of future illness rather than treating currently sympto-
matic disease.36 In other cases, patients are confused by conflict-
ing advice on benefit and harm from different health care
professionals. Personal costs of buying drugs and associated bur-
Table. The Deprescribing Protocol
Key Step
Detailed
Processes
1. Ascertain all drugs the patient is
currently taking and the reasons for
each one
Ask patients (and carers) to bring all drugs (prescribed, complementary and alternative medicine, and over the counter)
and drug delivery aids to consultation or home visit
Ask patients (in a nonjudgmental way) about any regularly prescribed drugs not being taken and if so why not (eg, too
expensive, adverse effects)
2. Consider overall risk of drug-induced
harm in individual patients in
determining the required intensity of
deprescribing intervention
Ascertain and assess risk according to
• Drug factors: number of drugs (single most important predictor), use of “high-risk” drugs (see text), past or
current toxicity
• Patient factors: age >80 y, cognitive impairment, multiple comorbidities, substance abuse, multiple prescribers,
past or current nonadherence
3. Assess each drug for its eligibility to
be discontinued:
• No valid indication
• Part of a prescribing cascade
• Actual or potential harm of a drug
clearly outweighs any potential benefit
• Disease and/or symptom control drug
is ineffective or symptoms have
completely resolved
• Preventive drug is unlikely to confer
any patient-important benefit over the
patient’s remaining lifespan
• Drugs are imposing unacceptable
treatment burden
Identify drugs being prescribed
For a diagnosis that is in doubt, ie, not confirmed; highly atypical presentations;
For a confirmed diagnosis but in which evidence of efficacy is nonexistent (eg, ivabradine being prescribed for stable
angina despite randomized trials showing no benefit); or
That confer no additional benefit after a certain period of continuous use (such as bisphosphonates taken for more
than 5 y) or after a certain age (such as hormone therapy in patients older than 70 y)
Identify drugs prescribed to counteract adverse effects of other drugs (eg, potassium supplements to counteract
effects of diuretics prescribed for ankle swelling secondary to calcium channel blocker use)
Reconsider the indications for the initial culprit drug or its substitution by an alternative drug with superior tolerability
Identify “drugs to avoid” in older patients (see text)
Identify drugs contraindicated in particular patients (eg, β-blockers in an asthmatic patient)
Identify drugs causing well-known adverse effects (eg, constipation with calcium antagonists; postural symptoms with
α-blockers)
Ask patient, “Since you started this medicine, has it made such a difference to how you feel that you would prefer to
stay on it?” and consider discontinuing the drug if the response is no or probably not
Ask, “Are you still experiencing any troublesome symptoms (cough, headache, dyspepsia, etc)? Do you feel the
medicine is still required?”
Consider discontinuing use of the drug if the target condition is self-limiting, mild, intermittent, or amenable to
nondrug interventions (eg, change in diet, alcohol use)
Estimate patient’s life expectancy using risk prediction tools or asking “surprise” question (see text)
Determine the patient’s expectations and preferences—is present-day quality of life more important than prolonging
life or preventing future morbid events?
Identify drugs unlikely to confer benefit (and that may cause harm) over the patient’s remaining lifespan
Ask the patient, “Apart from side effects, are there any other concerns you have with your medicines?”
Identify drugs that are particularly burdensome (eg, difficulty swallowing large tablets, out-of-pocket expense,
monitoring requirements [such as warfarin sodium])
4. Prioritize drugs for discontinuation Deciding the order of discontinuation of drugs may depend on integrating 3 pragmatic criteria:
(1) those with the greatest harm and least benefit;
(2) those easiest to discontinue, ie, lowest likelihood of withdrawal reactions or disease rebound;
(3) those that the patient is most willing to discontinue first (to gain buy-in to deprescribing other drugs)
Suggested approach is to rank drugs from high harm/low benefit to low harm/high benefit and discontinue the former
in sequential order (Figure)
5. Implement and monitor drug
discontinuation regimen
Explain and agree with patient on management plan
Cease 1 drug at a time so that harms (withdrawal reactions or return of disease) and benefits (resolution of adverse
drug effects) can be attributed to specific drugs and rectified (if necessary)
Wean patients off drugs more likely to cause adverse withdrawal effects, instruct patient (or carer) on what to look for
and report in the event of such effects occurring, and what actions they can self-initiate if these were to occur
Communicate plan and contingencies to all health professionals and other relevant parties (carers, family) involved in
patient’s care
Fully document the reasons for, and outcomes of, deprescribing
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dens ofmonitoring are additional disincentives. By eliminating un-
necessary drugs, deprescribing may improve overall adherence to
essential drugs while reducing costs and inconvenience.37
Does the Drug FitWith the Patient’s Life Circumstances?
Drugs are rarely indicated if they do not confer a patient-important
benefitwithin the context of one’s life circumstances. Patientswith
severedementia,end-stageorganfailure,ormetastaticcancerwould
derive little benefit from preventive drugs such as bisphospho-
nates and statins in the relatively short time prior to death.
Does the Likely Benefit of the Drug Outweigh Its Potential
for Harm?
Olderpatientsareparticularlyvulnerable toadverseeffects fromcer-
tain classes of drugs. These “high-risk” drugs include opioids, ben-
zodiazepines, psychotropic drugs, nonsteroidal anti-inflammatory
drugs, anticoagulants, digoxin, cardiovascular drugs, hypoglyce-
mic agents, anddrugswith anticholinergic effects. “High-risk” drug
combinations are those inwhicheach individual drugaugments the
level of toxicity, suchas the “triplewhammy”of nonsteroidal agent,
diuretic, andangiotensin-convertingenzyme inhibitor inpeoplewith
chronic kidney disease.
When considering deprescribing, it helps to group drugs into
2 categories, while acknowledging that some drugs may appear
in both:
Diseaseand/or symptomcontrol drugs: those that control activedis-
easeandsymptomsandmaintainqualityof life (eg, analgesics, anti-
anginals, anti–heart failure drugs, levothyroxine sodium). In many
instances, if treatmentwith thesedrugs is ceased,patients are likely
toquicklybecomesymptomaticor lose function fromworseningdis-
ease. This is not to suggest that thesedrugs couldnotbeceaseden-
tirely if proving to be ineffective, or reduced in dose or used as re-
quired if diseasemanifestationsaremildor intermittent.Aggressive
use of drugs aimedat controlling hypertensionor diabetesmellitus
shouldbeavoided inolder patients because theymaydo little to al-
ter symptomsor change thenatural historyof thedisease,while ex-
posing patients to more immediate threats of hypotension or hy-
poglycemia.
Preventive drugs: those that prevent future morbid events (eg,
statins, warfarin sodium, bisphosphonates). Deciding to discon-
tinue prescribing these drugs involves consideration of the abso-
lute risks and benefits of treatment for individual patients, the
length of time required for benefit to manifest (time to benefit)38
in cases in which therapy has been recently commenced (or is
being considered), and patient preferences and estimated lifes-
pan. Estimating life expectancy can be difficult, although the
simple “surprise” question, “knowing all that I know about this
patient, would I be surprised if he or she were to die in the next 12
months?” is reasonably predictive.39
Instances inWhich Deprescribing
Should Be Considered
Deprescribing should be especially considered in any older patient
• presenting with a new symptom or clinical syndrome suggestive
of adverse drug effects;
• manifesting advanced or end-stage disease, terminal illness, de-
mentia, extreme frailty, or full dependence on others for all care;
• receiving high-risk drugs or combinations;
• receiving preventive drugs for scenarios associated with no in-
creaseddisease riskdespitedrugcessation (eg,discontinuingalen-
dronate sodiumtherapyafter 5 yearsof treatment results inno in-
crease in osteoporotic fracture risk over the ensuing 5 years40;
ceasing use of statins for primary prevention after some years
results in no increase in cardiovascular events 8 years after
discontinuation41).
Barriers to Deprescribing
Systematic reviewsofqualitative research42,43 suggest that,within
prescriber-patient interactions, bothparticipants are challengedby
high levels of clinical complexity, limited consultation time, frag-
mented care among multiple prescribers, incomplete information
(on past rationales for, and patient tolerance of, drugs), ambiguous
Figure. Algorithm for Deciding Order andMode inWhich Drug Use Could Be Discontinued
1. No benefit 
Significant toxicity OR no indication OR obvious
contraindication OR cascade prescribing?
4. Preventive drugs
Potential benefit unlikely to be realized
because of limited life expectancy?
Symptoms stable or nonexistent?3. Symptom or disease drugsSymptoms stable or nonexistent?
Continue drug therapy Discontinue drug therapy Restart drug therapy
2. Harm outweighs benefit
Adverse effects outweigh symptomatic
effect or potential future benefits?
Taper dose and monitor for adverse drug
withdrawal effects
Withdrawal symptoms or disease recurrence
likely if drug therapy discontinued?
Yes
Yes Yes
Yes
No
No
No
No
No
No
YesYes
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or changing care goals, uncertainty about the benefits and harms
of continuing or discontinuing specific drugs, and community and
professional attitudes toward more rather than less use of drugs.
Bothparties fearadversedrugwithdrawaleffects,eventhoughthese
occur much less frequently than adverse drug effects.22,44
Another barrier is the pressure to prescribe evoked by recom-
mendationscontainedwithindisease-specificclinicalguidelines.While
intending to optimize care, such recommendations may be less ap-
plicable to older,multimorbid patientswith polypharmacy,45,46 par-
ticularly if based on clinical trials that have excluded such patients.
Strategies That Can Assist Deprescribing
Assistive strategies can operate at the level of individual clinical
encounters or at the level of whole populations and systems of
care. Within encounters, patients should be empowered to ask
their physicians and pharmacists the following questions: what are
the treatment options (including nondrug options) for my condi-
tion; what are the possible benefits and harms of each treatment
(drug); and what might be reasonable grounds for discontinuing
Box. System-Level Strategies for Facilitating Deprescribing in Clinical Practice
Professional Societies of Prescribers (Primary Care, Specialists,
Pharmacists, Dentists, Nurse Practitioners)
Develop position statements on high-quality use of drugs in older,
multimorbid populations that include and integrate the concept of
deprescribing
Provide training, professional development programs, workshops,
and seminars that impart knowledge and skills in appropriate
initiation, monitoring, evaluation, and cessation of drug use
Universities and Research Bodies
Incorporate appropriately tailored curricula in high-quality use of
drugs that integrate deprescribing in all undergraduate, graduate,
and postgraduate courses in medicine, pharmacy, nursing, dentistry,
and allied health
Require funding and ethics approval for research projects involving
drugs to collect, analyze, and report data that relate to frequency of,
and reasons for, withdrawal of drug use in trial participants to build
the evidence base of drug-related harm
Clinical Guideline Developers
Develop treatment recommendations specific to the needs of older,
multimorbid patients that acknowledge the limited evidence base
for use of many drugs in such populations
Make explicit reference to commonly encountered clinical scenarios
in which use of disease-specific drugs may engender greater risk of
harm as a result of drug-drug and drug-disease interactions; include
cautionary notes regarding initiation or discontinuation of drug use
in high-risk scenarios
Pharmacists and Pharmacy Services
Instruct patients in how to identify drug-induced harm and adverse
effects and how to collaborate with their prescribing clinicians in
safely discontinuing use of high-risk drugs
Incorporate into practice standards the requirement that
pharmacists be assigned to residential care facilities for the purpose
of achieving high-quality use of drugs, reviewing drug lists, and
highlighting instances amenable to deprescribing
Organizations and Services Responsible for ProvidingHigh-Quality
Use of Drug Information or Issuing DrugHandbooks, Prescribing
Guidelines, andDrug Safety Bulletins
Include information on strategies for therapy cessation in drug
handbooks and prescribing guidelines with cross-reference to drug
classes and circumstances in which use of specific drugs should be
avoided in older, multimorbid populations
Require drug prescribing software vendors to incorporate flags and
alerts that prompt prescribers to consider therapy cessation in
at-risk patients
Establish websites that provide tools and resources for health care
professionals in how to undertake appropriate deprescribing of
drugs
Government and Statutory Bodies (Health Departments, Quality
and Safety Commissions, Practice Accreditation Services, Health Care
Standard–Setting Bodies)
Fund research to develop and evaluate drug safety standards that
maximize the potential for reducing inappropriate use of drugs
Identify best practices with regard to the timeliness (when and how
often), setting (hospital, primary care, residential aged care facility),
and participants (clinical pharmacists, physicians, nurses) of drug
review that will enable sustainable interventions supporting therapy
cessation
Incorporate formal education and quality measurement systems
that support andmonitor patients receiving multiple drugs within
hospital and primary care accreditation procedures
Issue drug-specific prescribing alerts when pharmacovigilance data
suggest higher than expected incidence of drug-related adverse
events in older populations
Revise national policies and strategies for high-quality use of drugs
to ensure that the concept of deprescribing is integratedmore
clearly into the definition of high-quality use of drugs
Clinical Researchers
Design and conduct clinical trials that recruit older, multimorbid
patients, including specific subgroups (eg, patients with dementia)
and aim to define drug benefits and harms using patient stratification
methods
Adopt the word “deprescribing” in abstract titles as the accepted,
universal term for research on prescriber-mediated drug therapy
discontinuation so that relevant articles can bemore accurately
indexed in bibliographic databases andmore easily retrieved in
literature searches
Medical Journals
Publish prescribing position statements, guides, resources, and
clinical vignettes that support appropriate prescribing and integrate
deprescribing issues
Residential Aged Care Facilities
Incorporate into practice standards the requirement for training of
aged care workers in high-quality use of drugs and pharmacist
reviews
Incorporate into accreditation standards the requirement for drug
review for every patient newly admitted to an aged care facility and
returning after recent hospitalization
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use of a drug. In turn, physicians and pharmacists should ask, at
every encounter, whether patients are experiencing any adverse
effects, unwanted reactions, or administration and monitoring
problems in association with any of their drugs. Collaborative
prescriber-pharmacist review of drugs that uses validated criteria
to identify drugsmore likely to be unnecessary or harmful can help
initiate and guide deprescribing.47,48 In estimating treatment
benefit-harmtrade-offs in individual patients, prediction tools (http:
//www.medal.org/), evidence tables,49 and decision aids that esti-
mate absolute disease risk, and absolute treatment benefit and
harm for various conditions are increasingly available. Finally, prac-
tical guidance in how to safely wean and cease use of particular
classes of drugs in older people is now easily accessible.50 At the
system of care level, deprescribing efforts will be compromised in
realizing better population health unless all key stakeholders
involved in high-quality use of drugs commit to implementing
strategies that recognize deprescribing as an integral part of good
clinical care (Box).
Areas Requiring More Research
Future research into the incidence, causes, and remediationofover-
prescribing of inappropriate drugs in older patients should con-
sider several key questions:
• Towhatextentdoesa standardizeddeprescribingapproachaffect
patient adherence to essential drugs, overall drug costs (to the in-
dividual as well as the public purse), patient satisfaction and self-
management, and long-term clinical outcomes?
• Under what circumstances could deprescribing confer negative,
irreversible effects in both the short and long term?
• What is themost effective, cost-effective, and practical approach
to deprescribing in routine clinical settings?
• Whatare theabsoluteestimatesofdrug-inducedbenefit andharm,
and timeuntil benefit, for specificdrugclassesofpreventivedrugs
related to specific clinical scenarios?
• How can these benefit-harm estimates be accessed and pre-
sented within prescriber-patient encounters in ways that opti-
mally inform deprescribing decisions?
Conclusions
Inappropriate drug use and its associated harm is a growing issue
among older patients. It calls for deliberate yet judicious prescrib-
ing that includes a systematic approach toward deprescribing ap-
plied by all prescribers and supported and reinforced by pharma-
cists andothers responsible foroptimizinguseofdrugs.Widespread
adoption of a deprescribing protocol in clinical care has its chal-
lenges but also considerable potential to relieve unnecessary suf-
fering and disability in older patients.More high-quality research is
needed in defining the circumstances under which deprescribing
confersmaximalbenefit in termsof improvedclinical outcomesand
should bemore widely practiced.
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